

HB0308S01 compared with HB0308

~~text~~ shows text that was in HB0308 but was deleted in HB0308S01.

text shows text that was not in HB0308 but was inserted into HB0308S01.

DISCLAIMER: This document is provided to assist you in your comparison of the two bills. Sometimes this automated comparison will NOT be completely accurate. Therefore, you need to read the actual bills. This automatically generated document could contain inaccuracies caused by: limitations of the compare program; bad input data; or other causes.

Representative Steve Eliason proposes the following substitute bill:

PRESCRIPTION DRUG AMENDMENTS

2022 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Steve Eliason

Senate Sponsor: ~~_____~~ Evan J. Vickers

LONG TITLE

General Description:

This bill amends provisions relating to drug pricing.

Highlighted Provisions:

This bill:

- ▶ modifies provisions relating to reimbursement and contracting for pharmaceutical drugs;
- ▶ enacts new prohibitions on pharmacy benefit managers ~~and insurers~~ regarding drug pricing and contracting for 340B entities and 340B drugs;
- ▶ prohibits a pharmaceutical manufacturer from engaging in certain types of actions with respect to pharmacies and 340B entities; and
- ▶ provides an immediate effective date for the bill.

Money Appropriated in this Bill:

HB0308S01 compared with HB0308

None

Other Special Clauses:

This bill provides a special effective date.

This bill provides revisor instructions.

Utah Code Sections Affected:

AMENDS:

31A-46-309, as enacted by Laws of Utah 2020, Chapter 275

ENACTS:

31A-46-311, Utah Code Annotated 1953

Utah Code Sections Affected by Revisor Instructions:

31A-46-309, as enacted by Laws of Utah 2020, Chapter 275

Be it enacted by the Legislature of the state of Utah:

Section 1. Section **31A-46-309** is amended to read:

31A-46-309. Reimbursement -- Prohibitions.

(1) This section applies to a contract that is entered into, amended, or renewed on or after [January 1, 2021] the effective date of this bill, between a ~~{pharmacy and a }~~pharmacy benefit manager ~~{}~~and a pharmacy~~{ or an insurer}~~.

(2) A pharmacy benefit manager ~~{or an insurer }~~may not vary the amount it reimburses a pharmacy for a drug on the basis of whether:

- (a) the drug is a 340B drug; or
- (b) the pharmacy is a 340B entity.

(3) Subsection (2) does not apply to a drug reimbursed, directly or indirectly, by the Medicaid program.

(4) A pharmacy benefit manager ~~{or an insurer }~~may not:

(a) on the basis that a 340B entity participates, directly or indirectly, in the 340B drug discount program:

(i) refuse to contract with the 340B entity;

~~{(i)}~~ (ii) assess a fee, charge-back, or other adjustment on the 340B entity;

~~{(ii)}~~ (iii) restrict access to the pharmacy benefit manager's pharmacy network;

~~{(iii)}~~ (iv) require the 340B entity to enter into a contract with a specific pharmacy to

HB0308S01 compared with HB0308

participate in the pharmacy benefit manager's pharmacy network;

~~[(iv)]~~ (v) create a restriction or an additional charge on a patient who chooses to receive drugs from a 340B entity; ~~[or]~~

(vi) modify a copayment or other cost-sharing requirement of a patient of the 340B entity; or

~~[(v)]~~ (vii) create any additional requirements or restrictions on the 340B entity; ~~[or]~~

(b) require a claim for a drug to include a modifier to indicate that the drug is a 340B drug unless the claim is for payment, directly or indirectly, by the Medicaid program~~[-]~~;

(c) require a pharmacy to reverse, resubmit, or clarify a claim for a ~~{340B}~~ drug after an initial adjudication for the purpose of determining whether the drug is a 340B drug;

(d) base a drug formulary decision or a drug coverage decision on whether:

(i) a drug is a 340B drug; or

(ii) a pharmacy is a 340B entity;

(e) transfer the benefit of 340B drug discount program savings from a 340B entity to another entity;

(f) unilaterally modify the definition of pharmacy in a way that is inconsistent with state law through a contract, a provider manual, or other means; or

(g) directly or indirectly charge or hold a 340B entity responsible for a fee related to a claim:

(i) that is not apparent at the time of claim processing;

(ii) that is not reported on the remittance advice of an adjudicated claim; or

(iii) after the initial claim is adjudicated at the point of sale.

Section 2. Section **31A-46-311** is enacted to read:

31A-46-311. Prohibited acts by pharmaceutical manufacturers.

A pharmaceutical manufacturer, or any person involved in the distribution of a pharmaceutical manufacturer's products, may not:

(1) prohibit a pharmacy from contracting or participating with a 340B entity by denying the pharmacy or 340B entity access to drugs manufactured by the pharmaceutical manufacturer; or

(2) deny or prohibit 340B drug discount program pricing for a 340B entity.

Section 3. **Effective date.**

HB0308S01 compared with HB0308

If approved by two-thirds of all the members elected to each house, this bill takes effect upon approval by the governor, or the day following the constitutional time limit of Utah Constitution, Article VII, Section 8, without the governor's signature, or in the case of a veto, the date of veto override.

Section 4. Revisor instructions.

The Legislature intends that the Office of Legislative Research and General Counsel, in preparing the Utah Code database for publication, replace the references in Subsection 31A-46-309(1) from "the effective date of this bill" to the bill's actual effective date.